Summary
AstraZeneca to pay $21 per Fusion share
Deal valued at $2.4 bln with contingent value right of $3/share
Deal has solid strategic logic – JPM
March 19 (Reuters) – AstraZeneca (AZN.L), opens new tab said on Tuesday it will buy Canadian drug developer Fusion Pharmaceuticals Inc (FUSN.O), opens new tab for $2 billion in cash as the Anglo-Swedish drugmaker bets on next-generation cancer treatments.
The deal gives AstraZeneca a foothold in the radiopharmaceutical drugs market, which has seen increasing investor interest since 2021 when data from Novartis’ (NOVN.S), opens new tab treatment showed that the drug extended survival for prostate cancer patients.

Posted in

Iron Will

Leave a Comment

You must be logged in to post a comment.